Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

NMT1 (N-myristoyltransferase 1)

Written2010-11Ponniah Selvakumar, Sujeet Kumar, Jonathan R Dimmock, Rajendra K Sharma
Department of Pathology, Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N OW8, Canada (PS, SK, RKS); Cancer Research Unit, Saskatchewan Cancer Agency, 20 Campus Drive, Saskatoon, SK S7N 4H4, Canada (PS, SK, RKS); Drug Design, Discovery Research Group, College of Pharmacy, Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5C9, Canada (JRD)

(Note : for Links provided by Atlas : click)


Alias_symbol (synonym)NMT
Other alias
HGNC (Hugo) NMT1
LocusID (NCBI) 4836
Atlas_Id 43604
Location 17q21.31  [Link to chromosome band 17q21]
Location_base_pair Starts at 45061299 and ends at 45109014 bp from pter ( according to hg19-Feb_2009)  [Mapping NMT1.png]
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
CLN8 (8p23.3) / NMT1 (17q21.31)HEXIM2 (17q21.31) / NMT1 (17q21.31)ITSN2 (2p23.3) / NMT1 (17q21.31)
NMT1 (17q21.31) / NME1-NME2 (17q21.33)NMT1 (17q21.31) / NMT1 (17q21.31)NMT1 (17q21.31) / ST5 (11p15.4)
TMEM106A (17q21.31) / NMT1 (17q21.31)TMEM259 (19p13.3) / NMT1 (17q21.31)


Description The gene located on the forward strand and spans a size of 47705 bases. It starts at 43138680 and ends at 43186384 bp from pter. The total number of exons is 12.
Transcription Alternate splicing.
Pseudogene No known pseudogenes.


Description N-myristoyltransferase 1 (NMT 1: EC is a key cellular enzyme which carries out lipid modification by facilitating the attachment of myristate to the N-terminal glycine of several protein molecules. The enzyme's function is indispensible for the growth and development of many eukaryotic organisms and several rotaviruses (Duronio et al., 1989; Duronio et al., 1991; Maurer-Stroh and Eisenhower, 2004; Yang et al., 2005; Wright et al., 2009). The best studied homologue of NMT1 is from the S. cerevisiae (Farazi et al., 2001). It is a monomer and does not require any cofactor or post-translational modifications. The enzyme follows an ordered Bi Bi reaction mechanism in which the apo-enzyme binds myristoyl-CoA to form a NMT1-myristoyl-CoA binary complex which subsequently binds to protein/peptide substrates. The catalytic conversion (N-myristoylation) is via a direct nucleophilic addition-elimination reaction. The sequential release of CoA and myristoyl-peptide follows the formation of an enzyme-product complex from the enzyme-substrate complex (Farazi et al., 2001; Wright et al., 2009). N-myristoyltransferases 1 have a common preference for myristoyl-CoA but have divergent peptide substrate specificities and the enzyme is highly selective for myristoyl-CoA in vitro and in vivo (Farazi et al., 2001). The protein belongs to GNAT superfamily of enzymes and consists of a saddle-shaped beta-sheet flanked by a helices. There is a pseudo two fold symmetry with regions corresponding to N- and C-terminal portions of the enzyme. The N-terminal half forms the myristoyl-CoA binding site whereas the C-terminal half forms the major portion of the peptide binding site (Farazi et al., 2001; Wright et al., 2009). A large number of crystal structures of NMT1 from yeast and human isoforms are available in apo and complex form. Comparative analysis of the various NMTs has shown that the peptide binding pocket is more divergent than the myristoyl-CoA-binding site (Farazi et al., 2001; Wright et al., 2009). Further, the phospho-proteome analysis studies have shown that the human isoform is phosphorylated in vivo at position 47 (Beausoleil et al., 2004; Beausoleil et al., 2006; Olsen et al., 2006; Dephoure et al., 2008; Mayya et al., 2009). However the biological significance of this observation is not yet established.
Expression The enzyme is ubiquitous in expression and often exists as isozymes in vivo, varying in either apparent molecular weight and/or subcellular distribution (Selvakumar et al., 2007; Wright et al., 2009). In humans NMT1 is processed to exist as four distinct isoforms ranging from 49 to 68 kDa in size (Giang and Cravatt, 1998). The longer isoform of 496 amino acids represents the full-length protein whereas the shorter isoform represents a translation product of 416 amino acids that initiates with a methionine at amino acid position 81 in the full-length cDNA (Giang and Cravatt, 1998; Farazi et al., 2001). The shorter isoform of NMT1 may arise from an alternative splice variant or through initiation of translation at an internal methionine.
Localisation NMT1 is a cytoplasmic enzyme because of N-myristoylation being a co-translational protein modification. Recently, it has been reported that the extended N-terminal domain of the longer isoform of NMT1 is involved in targeting the enzyme to the ribosome but it is not required for activity in vitro (Glover et al., 1997). Targeting to the ribosome appears to be consistent with its role as a co-translational protein modifier. In previous studies it has been observed that NMT1 activity from various cell lines and tissues is associated with membranous and particulate fraction (Magnuson et al., 1995; Boutin, 1997). However, the enzyme activity in particulate fractions in earlier studies could represent an association with ribosomes, rather than an authentic membrane association.
Function N-myristoyltransferase1 catalyses the covalent attachment of myristate, a 14 carbon saturated fatty acid, via amide bond to the N-terminal glycine residue of several proteins (Wright et al., 2009; Hannoush and Sun, 2010). This lipidic modification is an irreversible process, however not without exceptions (Hannoush and Sun, 2010). Intially this process was thought to be co-translational in which the addition of myristate on the N-terminal glycine takes place after initial amino acid residues (within 100) have been synthesized by the ribosome (Wilcox et al., 1987). The process follows after the removal of the initiator methionine by a methionine aminopeptidase to expose an available N-terminal glycine. However, now it has been shown to occur post-translationally as well when an internal glycine within a polypeptide chain is exposed following a proteolytic cleavage (Zha et al., 2000; Utsumi et al., 2003; Martin et al., 2008). The Availability of exposed N-terminal glycine is an absolute requirement and the modification occurs on a general consesus motif of GXXXS/T (where X is any amino acid) (Boutin, 1997; Resh, 1999; Farazi et al., 2001; Wright et al., 2009; Hannoush and Sun, 2010).
Various regular endogenous, physiological enzymes and proteins such as protein kinase A, protein kinase G, NADH-cytochrome b5 reductase, nitric oxide synthase, recoverin, most of the G protein a subunit are the substrates of myristoylation among higher eukaryotes. A detailed list of the substrate proteins is available in a number of reviews elsewhere (Boutin, 1997; Resh, 1999; Maurer-Stroh et al., 2004; Selvakumar et al., 2007). Myristoylation increases protein lipophilicity and is important for the full expression of biological functions of proteins. It controls the functioning of proteins by targeting them to specific localization, promoting specific protein-protein and protein-lipid interactions and ligand-induced conformational changes (Resh, 1999; Farazi et al., 2001; Wright et al., 2009).

Implicated in

Entity Various cancers
Note Altered NMT expression is observed in many types of cancer tissues including those of colon, breast, gallbladder and brain (Selvakumar et al., 2007; Wright et al., 2009). A quantitative RT-PCR investigation of hNMT-1 expression during the progression of different human cancers shows that hNMT-1 is upregulated in breast, colon, lung and on average by 3.7 (p=0.032), 3.1 (p=0.001), 2.3 (p=0.003) and 1.8 (p=0.012) fold, respectively (Chen et al., 2009). These findings are explained by the hypothesis that many of the various proteins/oncoproteins (src, ras etc.) which are overexpressed and activated, during tumorigenesis require myristoylation for their proper function (Boutin, 1997; Resh, 1999; Wright et al., 2009). The elevated NMT activity accounts for the functioning of overexpressed oncoproteins and NMT thus plays a role in cancer progression. The NMT substrate src has elevated activity in human cancers and this contributes to its pathogenicity (Frame, 2002). Inhibiting NMT1 functions has also been shown to reduce proliferation and induce apoptosis in human and murine melanoma cell lines and also to block tumor growth in vivo (Bhandarkar et al., 2008). The siRNA mediated NMT1 knockdown shows that silencing NMT1 inhibits cell replication associated with loss of c-Src activation and its target FAK as well as reduction of various protein kinase regulated pathways (Ducker et al., 2005). The knockdown of either of the isozymes, NMT1 or NMT2 results in apoptosis with NMT2 having a more pronounced effect than NMT1. However, in a mouse model the intratumoral injection mainly of NMT1 siRNA has been shown to be responsible for inhibition of tumor growth (Ducker et al., 2005). It has been concluded that among the two isoforms of NMT (NMT1 and NMT2), both have only partially overlapping functions and that NMT1 is critical for tumor cell proliferation further suggesting that isoform-specific inhibitors might be developed as potential anti-cancer agents (Ducker et al., 2005). It is now apparent that NMT represents both a valuable clinical marker and therapeutic target for cancer (Boutin, 1997; Ducker et al., 2005; Selvakumar et al., 2007; Wright et al., 2009). A several fold increase in NMT activity in polyps and stage B1 tumors compared to normal colonic mucosa have been proposed to be used as a diagnostic/prognostic tool for early detection of colorectal cancer (Raju et al., 1997; Shrivastav et al., 2007; Kumar et al., 2011).
Entity Colorectal cancer
Disease Colorectal cancer is associated with significantly high mortality and is one of the most common forms of malignancy world wide (Segal and Saltz, 2009). In the western world, it accounts for the second most common cause of cancer associated deaths (Midgley and Kerr, 2001; Tol and Punt, 2010) and is the fourth most common cause of malignancy in the United States (Wolpin et al., 2007; Wolpin and Mayer, 2008). A majority of colon cancer develop from the pre-cancerous polyps on the lining of the colon which grow over the years to becomes cancerous in nature (Midgley and Kerr, 1999). With the increasing armentarium towards colon cancer (Midgley and Kerr, 1999; Midgley and Kerr, 2001; Wolpin et al., 2007; Wolpin and Mayer, 2008; Segal and Saltz, 2009; Tol and Punt, 2010), it is one of the most curable forms of cancer if detected early. However, due to the lack of early symptoms, the majority of the patients have an advanced disease at presentation (Midgley et al., 2001; Segal and Saltz, 2009). Studies have shown that NMT represents both a valuable marker for clinical diagnosis and as a therapeutic target for colon cancer (Magnuson et al., 1995; Raju et al., 1997; Shrivastav et al., 2007; Kumar et al., 2011).
Prognosis A direct relationship has been reported for NMT expression and activity and colon cancer progression (Magnuson et al., 1995; Raju et al., 1997). NMT activity and expression has been shown to be upregulated during the progression of colorectal cancer (Magnuson et al., 1995; Raju et al., 1997) and NMT thus has been proposed as a potential chemotherapeutic target (Felsted et al., 1995). A significantly higher NMT activity in rat colonic tumors and a several fold increase in NMT activity in polyps and stage B1 tumors compared to normal colonic mucosa have indicated that NMT could be used as a diagnostic/prognostic tool for colorectal cancer (Magnuson et al., 1995; Raju et al., 1997; Shrivastav et al., 2007). Altered expression and localization of NMT in the peripheral blood and bone marrow of colon cancer patients have offered an advantage for early detection of colorectal cancer using NMT as a blood based marker (Shrivastav et al., 2007; Kumar et al., 2011). The immunohistochemical analysis shows weak to negative staining for NMT in peripheral blood mononuclear cells (PBMC) of controls, whereas strong positivity is observed in the PBMC of colon cancer patients (Shrivastav et al., 2007; Kumar et al., 2011). In addition, NMT is confined mostly in the nuclei of the bone marrow (BM) mononuclear cells of the colon cancer patients, whereas in the control bone marrow specimens it remained cytoplasmic. The strikingly different NMT expression and its altered localization offers the basis of a potential adjunct investigative tool for screening or diagnosis of patients at risk for, or suspected of having, colon cancer (Shrivastav et al., 2007; Kumar et al., 2011). It has been observed that in colon cancer cell lines, an elevated expression of NMT correlates with high levels of c-Src levels (Rajala et al., 2000a). Further it has been observed that the levels of the myristoylated tyrosine kinases, pp60c-src and pp60c-yes are several fold higher in colonic preneoplastic lesions and neoplasms compared with normal colon cells (Bolen et al., 1987; Weber et al., 1992; Termuhlen et al., 1993). Differential expression of pp60c-src has been observed in colonic tumor-derived cell lines (Bolen et al., 1987; Weber et al., 1992) and colonic polyps prone to developing cancer (Cartwright et al., 1990). In the intestinal crypt cells, higher levels of cytoskeletal-associated pp60c-src protein tyrosine kinase activity have been observed along with higher expression of pp60c-yes in the normal intestinal epithelium (Zhao et al., 1990; Cartwright et al., 1993). Studies have revealed that pp60c-src is overexpressed in human colon carcinoma and it has enhanced kinase activity in progressive stages and metastases of human colorectal cancer (Bolen et al., 1987; Termuhlen et al., 1993). Furthermore, it has been shown that src kinase activity is positively regulated by myristoylation and the non-myristoylated c-Src exhibited has reduced kinase activity (Patwardhan and Resh, 2010). The blockages of pp60c-src N-myristoylation in colonic cell lines have been reported to result in depressed colony formation and reduced proliferation (Shoji et al., 1990).
Entity Gallbladder cancer
Disease Gallbladder cancer, also known as carcinoma of the gallbladder, is extremely rare affecting the gall bladder (the organ behind the liver which stores bile produced by the liver). Gallbladder is a non-essential organ and can be removed without significant consequences. However, since gallbladder cancer is very uncommon and many of its symptoms are similar to those of more common ailments (jaundice, pain, and fever), cancer of the gallbladder is usually not found until it is at an advanced stage and cannot be surgically removed.
Prognosis Gallbladder cancer tends to spread to the liver or small intestine and also spreads to lymph nodes through the lymphatic system in the region of the liver resulting in involvement of other lymph nodes and organs. The treatments available are not particularly effective, unless the tumor is very small and found in which case the gallbladder is removed for other reasons. A study of documented gallbladder carcinoma cases has been evaluated for NMT and p53 expression by immunohistochemistry in both in situ and in invasive tumor components (Rajala et al., 2000b). Moderate to strong cytoplasmic positivity for NMT with increased intensity in the invasive component was observed in 60% of the cases. A mild to moderate cytoplasmic staining was revealed in the in situ component in 67% of the cases studied. It has been concluded that increased NMT expression in gall bladder tumors is associated with poor clinical outcomes as evidenced by their mean survival times (Rajala et al., 2000b).
Entity Breast cancer
Disease Breast cancer originates from the breast tissue, most commonly from the inner lining of milk ducts (ductal carcinoma) or the lobules (lobular carcinoma) that supply the ducts with milk. It is the fifth most common cause of cancer death and comprises 10.4% of all cancer incidences among women worldwide, and is the most common type of non-skin cancer in women.
Prognosis It has been observed that in the mammary epithelial cells, the proliferative capacity correlates with NMT activity (Clegg et al., 1999). A study of the NMT profiles in tumourigenic or metastatic breast cancer cell lines have displayed reduced NMT activity and western blot analysis shows that NMT1 is phosphorylated in these breast cancer cells (Shrivastav et al., 2009). Furthermore, patients' breast cancer tissue array revealed strong positivity and high intensity for NMT in malignant breast tissues compared with normal breast cells. In the grade I, II, and III infiltrating ductal carcinoma breast tissues, a gradation in the NMT staining was observed (Shrivastav et al., 2009). It has been concluded that NMT may prove to be an additional diagnostic biomarker for breast cancer.
Entity HIV infection
Disease The human immunodeficiency virus (HIV) is a member of the retrovirus family (lentivirus) that causes acquired immune deficiency syndrome (AIDS). In this syndrome the immune system begins to fail leading to life-threatening opportunistic infections. The major routes of infections are via the transfer of blood, breast milk, semen, vaginal fluid and the pre-ejaculate. If left untreated, the progressive failure of the immune system results in opportunistic infections or malignancies leading to the death of individuals in most of the cases.
Prognosis The pathogenic states linked to undesired myristoylation activity includes the myristoylation of viral proteins for their proper maturation and infectivity (Boutin, 1997; Maurer-Stroh and Eisenhower, 2004; Wright et al., 2009). Many of the viral genes are homologues of the tyrosine kinases and require N-myristoylation for the infectivity of viral particles. In the case of HIV infections, viral proteins Gag and Nef require myristoylation by the host cell NMT to carry out their function properly. Gag is the precursor polyprotein for structural components of the viral capsid and requires myristoylation for intracellular localization and its targeting to the lipid rafts in the plasma membrane during virus assembly (Zhou et al., 1994; Resh, 2004; Wright et al., 2009). Nef on the other hand comprises many virulence factors to modify the cellular environment of infected cells to facilitate viral replication and evade detection by cells of the immune system (Collins et al., 1998). It has been reported that NMT1 myristoylates Gag in vivo and inhibiting NMT1 negatively affects HIV production (Takamune et al., 2008).


A probability-based approach for high-throughput protein phosphorylation analysis and site localization.
Beausoleil SA, Villen J, Gerber SA, Rush J, Gygi SP.
Nat Biotechnol. 2006 Oct;24(10):1285-92. Epub 2006 Sep 10.
PMID 16964243
Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo.
Bhandarkar SS, Bromberg J, Carrillo C, Selvakumar P, Sharma RK, Perry BN, Govindarajan B, Fried L, Sohn A, Reddy K, Arbiser JL.
Clin Cancer Res. 2008 Sep 15;14(18):5743-8.
PMID 18794083
Activation of pp60c-src protein kinase activity in human colon carcinoma.
Bolen JB, Veillette A, Schwartz AM, DeSeau V, Rosen N.
Proc Natl Acad Sci U S A. 1987 Apr;84(8):2251-5.
PMID 2436227
Boutin JA.
Cell Signal. 1997 Jan;9(1):15-35. (REVIEW)
PMID 9067626
Intestinal crypt cells contain higher levels of cytoskeletal-associated pp60c-src protein tyrosine kinase activity than do differentiated enterocytes.
Cartwright CA, Mamajiwalla S, Skolnick SA, Eckhart W, Burgess DR.
Oncogene. 1993 Apr;8(4):1033-9.
PMID 7681158
Quantitative Analysis of the Expression of Human N-myristoyltransferase 1 (hNMT-1) in Cancers.
Chen L, Ling B, Alcorn J, Yang J.
The open Biomarker Journal. 2009; 2: 6-10.
Expression of enzymes of covalent protein modification during regulated and dysregulated proliferation of mammary epithelial cells: PKA, PKC and NMT.
Clegg RA, Gordge PC, Miller WR.
Adv Enzyme Regul. 1999;39:175-203.
PMID 10470373
HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.
Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D.
Nature. 1998 Jan 22;391(6665):397-401.
PMID 9450757
A quantitative atlas of mitotic phosphorylation.
Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ, Gygi SP.
Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10762-7. Epub 2008 Jul 31.
PMID 18669648
Two N-myristoyltransferase isozymes play unique roles in protein myristoylation, proliferation, and apoptosis.
Ducker CE, Upson JJ, French KJ, Smith CD.
Mol Cancer Res. 2005 Aug;3(8):463-76.
PMID 16123142
Myristic acid auxotrophy caused by mutation of S. cerevisiae myristoyl-CoA:protein N-myristoyltransferase.
Duronio RJ, Rudnick DA, Johnson RL, Johnson DR, Gordon JI.
J Cell Biol. 1991 Jun;113(6):1313-30.
PMID 2045414
The biology and enzymology of protein N-myristoylation.
Farazi TA, Waksman G, Gordon JI.
J Biol Chem. 2001 Oct 26;276(43):39501-4. Epub 2001 Aug 29. (REVIEW)
PMID 11527981
Protein N-myristoylation as a chemotherapeutic target for cancer.
Felsted RL, Glover CJ, Hartman K.
J Natl Cancer Inst. 1995 Nov 1;87(21):1571-3.
PMID 7563194
Src in cancer: deregulation and consequences for cell behaviour.
Frame MC.
Biochim Biophys Acta. 2002 Jun 21;1602(2):114-30. (REVIEW)
PMID 12020799
A second mammalian N-myristoyltransferase.
Giang DK, Cravatt BF.
J Biol Chem. 1998 Mar 20;273(12):6595-8.
PMID 9506952
Human N-myristoyltransferase amino-terminal domain involved in targeting the enzyme to the ribosomal subcellular fraction.
Glover CJ, Hartman KD, Felsted RL.
J Biol Chem. 1997 Nov 7;272(45):28680-9.
PMID 9353336
The chemical toolbox for monitoring protein fatty acylation and prenylation.
Hannoush RN, Sun J.
Nat Chem Biol. 2010 Jul;6(7):498-506. (REVIEW)
PMID 20559317
N-Myristoyltransferase in Colon Cancer: A New Marker for Early Diagnosis.
Kumar S, Dimmock JR, Sharma RK.
Cancers (2011) (Special Issue "Cancer Diagnosis and Targeted Therapy). (Invited review, Manuscript in preparation)
Increased N-myristoyltransferase activity observed in rat and human colonic tumors.
Magnuson BA, Raju RV, Moyana TN, Sharma RK.
J Natl Cancer Inst. 1995 Nov 1;87(21):1630-5.
PMID 7563206
Rapid detection, discovery, and identification of post-translationally myristoylated proteins during apoptosis using a bio-orthogonal azidomyristate analog.
Martin DD, Vilas GL, Prescher JA, Rajaiah G, Falck JR, Bertozzi CR, Berthiaume LG.
FASEB J. 2008 Mar;22(3):797-806. Epub 2007 Oct 10.
PMID 17932026
MYRbase: analysis of genome-wide glycine myristoylation enlarges the functional spectrum of eukaryotic myristoylated proteins.
Maurer-Stroh S, Gouda M, Novatchkova M, Schleiffer A, Schneider G, Sirota FL, Wildpaner M, Hayashi N, Eisenhaber F.
Genome Biol. 2004;5(3):R21. Epub 2004 Feb 13.
PMID 15003124
Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.
Mayya V, Lundgren DH, Hwang SI, Rezaul K, Wu L, Eng JK, Rodionov V, Han DK.
Sci Signal. 2009 Aug 18;2(84):ra46.
PMID 19690332
Conventional cytotoxic and novel therapeutic concepts in colorectal cancer.
Midgley R, Kerr D.
Expert Opin Investig Drugs. 2001 Jun;10(6):1011-9.
PMID 11772231
Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.
Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, Mann M.
Cell. 2006 Nov 3;127(3):635-48.
PMID 17081983
Myristoylation and membrane binding regulate c-Src stability and kinase activity.
Patwardhan P, Resh MD.
Mol Cell Biol. 2010 Sep;30(17):4094-107. Epub 2010 Jun 28.
PMID 20584982
Expression of N-myristoyltransferase inhibitor protein and its relationship to c-Src levels in human colon cancer cell lines.
Rajala RV, Dehm S, Bi X, Bonham K, Sharma RK.
Biochem Biophys Res Commun. 2000a Jul 14;273(3):1116-20.
PMID 10891381
Increased expression of N-myristoyltransferase in gallbladder carcinomas.
Rajala RV, Radhi JM, Kakkar R, Datla RS, Sharma RK.
Cancer. 2000b May 1;88(9):1992-9.
PMID 10813869
N-Myristoyltransferase overexpression in human colorectal adenocarcinomas.
Raju RV, Moyana TN, Sharma RK.
Exp Cell Res. 1997 Aug 25;235(1):145-54.
PMID 9281363
A myristoyl switch regulates membrane binding of HIV-1 Gag.
Resh MD.
Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):417-8. Epub 2004 Jan 5.
PMID 14707265
N-Myristoyltransferase isozymes exhibit differential specificity for human immunodeficiency virus type 1 Gag and Nef.
Seaton KE, Smith CD.
J Gen Virol. 2008 Jan;89(Pt 1):288-96.
PMID 18089753
Evolving treatment of advanced colon cancer.
Segal NH, Saltz LB.
Annu Rev Med. 2009;60:207-19. (REVIEW)
PMID 19630571
Potential role of N-myristoyltransferase in cancer.
Selvakumar P, Lakshmikuttyamma A, Shrivastav A, Das SB, Dimmock JR, Sharma RK.
Prog Lipid Res. 2007 Jan;46(1):1-36. Epub 2006 Jun 12. (REVIEW)
PMID 16846646
Human cellular src gene product: identification of the myristoylated pp60c-src and blockage of its myristoyl acylation with N-fatty acyl compounds resulted in the suppression of colony formation.
Shoji S, Kurosawa T, Inoue H, Funakoshi T, Kubota Y.
Biochem Biophys Res Commun. 1990 Dec 31;173(3):894-901.
PMID 2268350
Overexpression of Akt/PKB modulates N-myristoyltransferase activity in cancer cells.
Shrivastav A, Varma S, Senger A, Khandelwal RL, Carlsen S, Sharma RK.
J Pathol. 2009 Jul;218(3):391-8.
PMID 19360752
HIV-1 production is specifically associated with human NMT1 long form in human NMT isozymes.
Takamune N, Gota K, Misumi S, Tanaka K, Okinaka S, Shoji S.
Microbes Infect. 2008 Feb;10(2):143-50. Epub 2007 Nov 5.
PMID 18248763
Site-specific differences in pp60c-src activity in human colorectal metastases.
Termuhlen PM, Curley SA, Talamonti MS, Saboorian MH, Gallick GE.
J Surg Res. 1993 Apr;54(4):293-8.
PMID 7687314
Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J, Punt CJ.
Clin Ther. 2010 Mar;32(3):437-53. (REVIEW)
PMID 20399983
C-terminal 15 kDa fragment of cytoskeletal actin is posttranslationally N-myristoylated upon caspase-mediated cleavage and targeted to mitochondria.
Utsumi T, Sakurai N, Nakano K, Ishisaka R.
FEBS Lett. 2003 Mar 27;539(1-3):37-44.
PMID 12650923
Differential pp60c-src activity in well and poorly differentiated human colon carcinomas and cell lines.
Weber TK, Steele G, Summerhayes IC.
J Clin Invest. 1992 Sep;90(3):815-21.
PMID 1381724
Acylation of proteins with myristic acid occurs cotranslationally.
Wilcox C, Hu JS, Olson EN.
Science. 1987 Nov 27;238(4831):1275-8.
PMID 3685978
Systemic treatment of colorectal cancer.
Wolpin BM, Mayer RJ.
Gastroenterology. 2008 May;134(5):1296-310. (REVIEW)
PMID 18471507
Protein myristoylation in health and disease.
Wright MH, Heal WP, Mann DJ, Tate EW.
J Chem Biol. 2009 Nov 7. (Epub ahead of print)
PMID 19898886
N-myristoyltransferase 1 is essential in early mouse development.
Yang SH, Shrivastav A, Kosinski C, Sharma RK, Chen MH, Berthiaume LG, Peters LL, Chuang PT, Young SG, Bergo MO.
J Biol Chem. 2005 May 13;280(19):18990-5. Epub 2005 Mar 7.
PMID 15753093
Posttranslational N-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis.
Zha J, Weiler S, Oh KJ, Wei MC, Korsmeyer SJ.
Science. 2000 Dec 1;290(5497):1761-5.
PMID 11099414
Expression of cellular-yes protein in mammalian tissues.
Zhao YH, Krueger JG, Sudol M.
Oncogene. 1990 Nov;5(11):1629-35.
PMID 2267131
Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids.
Zhou W, Parent LJ, Wills JW, Resh MD.
J Virol. 1994 Apr;68(4):2556-69.
PMID 8139035


This paper should be referenced as such :
Selvakumar, P ; Kumar, S ; Dimmock, JR ; Sharma, RK
NMT1 (N-myristoyltransferase 1)
Atlas Genet Cytogenet Oncol Haematol. 2011;15(7):570-575.
Free journal version : [ pdf ]   [ DOI ]
On line version :

Other Solid tumors implicated (Data extracted from papers in the Atlas) [ 3 ]
  t(2;17)(p23;q21) ITSN2/NMT1
NMT1/NME1-NME2 (17q21)
TMEM106A/NMT1 (17q21)

External links

HGNC (Hugo)NMT1   7857
Entrez_Gene (NCBI)NMT1  4836  N-myristoyltransferase 1
GeneCards (Weizmann)NMT1
Ensembl hg19 (Hinxton)ENSG00000136448 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000136448 [Gene_View]  ENSG00000136448 [Sequence]  chr17:45061299-45109014 [Contig_View]  NMT1 [Vega]
ICGC DataPortalENSG00000136448
TCGA cBioPortalNMT1
AceView (NCBI)NMT1
Genatlas (Paris)NMT1
SOURCE (Princeton)NMT1
Genetics Home Reference (NIH)NMT1
Genomic and cartography
GoldenPath hg38 (UCSC)NMT1  -     chr17:45061299-45109014 +  17q21.31   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)NMT1  -     17q21.31   [Description]    (hg19-Feb_2009)
GoldenPathNMT1 - 17q21.31 [CytoView hg19]  NMT1 - 17q21.31 [CytoView hg38]
Mapping of homologs : NCBINMT1 [Mapview hg19]  NMT1 [Mapview hg38]
Gene and transcription
Genbank (Entrez)AF020500 AF043324 AK291936 AK303517 BC006538
RefSeq transcript (Entrez)NM_021079
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)NMT1
Cluster EST : UnigeneHs.532790 [ NCBI ]
CGAP (NCI)Hs.532790
Alternative Splicing GalleryENSG00000136448
Gene ExpressionNMT1 [ NCBI-GEO ]   NMT1 [ EBI - ARRAY_EXPRESS ]   NMT1 [ SEEK ]   NMT1 [ MEM ]
Gene Expression Viewer (FireBrowse)NMT1 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevestigatorExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)4836
GTEX Portal (Tissue expression)NMT1
Human Protein AtlasENSG00000136448-NMT1 [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtP30419   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtP30419  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProP30419
Splice isoforms : SwissVarP30419
Domaine pattern : Prosite (Expaxy)NMT_1 (PS00975)    NMT_2 (PS00976)   
Domains : Interpro (EBI)Acyl_CoA_acyltransferase    MyristoylCoA_TrFase    MyristoylCoA_TrFase_C    MyristoylCoA_TrFase_CS    MyristoylCoA_TrFase_N   
Domain families : Pfam (Sanger)NMT (PF01233)    NMT_C (PF02799)   
Domain families : Pfam (NCBI)pfam01233    pfam02799   
Conserved Domain (NCBI)NMT1
DMDM Disease mutations4836
Blocks (Seattle)NMT1
PDB (RSDB)1RXT    3IU1    3IU2    3IWE    3JTK    4C2Y    4C2Z    5MU6    5UUT   
PDB Europe1RXT    3IU1    3IU2    3IWE    3JTK    4C2Y    4C2Z    5MU6    5UUT   
PDB (PDBSum)1RXT    3IU1    3IU2    3IWE    3JTK    4C2Y    4C2Z    5MU6    5UUT   
PDB (IMB)1RXT    3IU1    3IU2    3IWE    3JTK    4C2Y    4C2Z    5MU6    5UUT   
Structural Biology KnowledgeBase1RXT    3IU1    3IU2    3IWE    3JTK    4C2Y    4C2Z    5MU6    5UUT   
SCOP (Structural Classification of Proteins)1RXT    3IU1    3IU2    3IWE    3JTK    4C2Y    4C2Z    5MU6    5UUT   
CATH (Classification of proteins structures)1RXT    3IU1    3IU2    3IWE    3JTK    4C2Y    4C2Z    5MU6    5UUT   
Human Protein Atlas [tissue]ENSG00000136448-NMT1 [tissue]
Peptide AtlasP30419
IPIIPI00329692   IPI00218830   IPI01008919   
Protein Interaction databases
IntAct (EBI)P30419
Ontologies - Pathways
Ontology : AmiGOin utero embryonic development  glycylpeptide N-tetradecanoyltransferase activity  glycylpeptide N-tetradecanoyltransferase activity  cytoplasm  cytoplasm  mitochondrion  cytosol  cytosol  plasma membrane  N-terminal protein myristoylation  N-terminal peptidyl-glycine N-myristoylation  N-terminal peptidyl-glycine N-myristoylation  myristoyltransferase activity  myristoyltransferase activity  extrinsic component of membrane  regulation of rhodopsin mediated signaling pathway  cellular ketone metabolic process  positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway  
Ontology : EGO-EBIin utero embryonic development  glycylpeptide N-tetradecanoyltransferase activity  glycylpeptide N-tetradecanoyltransferase activity  cytoplasm  cytoplasm  mitochondrion  cytosol  cytosol  plasma membrane  N-terminal protein myristoylation  N-terminal peptidyl-glycine N-myristoylation  N-terminal peptidyl-glycine N-myristoylation  myristoyltransferase activity  myristoyltransferase activity  extrinsic component of membrane  regulation of rhodopsin mediated signaling pathway  cellular ketone metabolic process  positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway  
REACTOMEP30419 [protein]
REACTOME PathwaysR-HSA-75108 [pathway]   
NDEx NetworkNMT1
Atlas of Cancer Signalling NetworkNMT1
Wikipedia pathwaysNMT1
Orthology - Evolution
GeneTree (enSembl)ENSG00000136448
Phylogenetic Trees/Animal Genes : TreeFamNMT1
Homologs : HomoloGeneNMT1
Homology/Alignments : Family Browser (UCSC)NMT1
Gene fusions - Rearrangements
Fusion : MitelmanITSN2/NMT1 [2p23.3/17q21.31]  [t(2;17)(p23;q21)]  
Fusion : MitelmanNMT1/NME1-NME2 [17q21.31/17q21.33]  [t(17;17)(q21;q21)]  
Fusion : MitelmanTMEM106A/NMT1 [17q21.31/17q21.31]  [t(17;17)(q21;q21)]  
Fusion PortalITSN2 2p23.3 NMT1 17q21.31 BRCA
Fusion PortalNMT1 17q21.31 NME1-NME2 17q21.33 LUSC
Fusion PortalTMEM106A 17q21.31 NMT1 17q21.31 SKCM
Fusion : FusionGDB13609    17985    24511    24512    24513    24514    24515    24516    38348    38594    7445   
Fusion : Fusion_HubATP6V0D1--NMT1    BRCA1--NMT1    C19ORF6--NMT1    CLN8--NMT1    EXOSC5--NMT1    HDAC5--NMT1    HEXIM2--NMT1    ITSN2--NMT1    MYO5B--NMT1    NMT1--GNA13    NMT1--HIGD1B    NMT1--LRRC4B    NMT1--MPHOSPH8    NMT1--NME1-NME2    NMT1--NMNAT1   
NMT1--NMT1    NMT1--PABPC1    NMT1--ST5    SLC35C2--NMT1    TMEM106A--NMT1    YIPF1--NMT1   
Fusion : QuiverNMT1
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerNMT1 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)NMT1
Exome Variant ServerNMT1
ExAC (Exome Aggregation Consortium)ENSG00000136448
GNOMAD BrowserENSG00000136448
Varsome BrowserNMT1
Genetic variants : HAPMAP4836
Genomic Variants (DGV)NMT1 [DGVbeta]
DECIPHERNMT1 [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisNMT1 
ICGC Data PortalNMT1 
TCGA Data PortalNMT1 
Broad Tumor PortalNMT1
OASIS PortalNMT1 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICNMT1  [overview]  [genome browser]  [tissue]  [distribution]  
Somatic Mutations in Cancer : COSMIC3DNMT1
Mutations and Diseases : HGMDNMT1
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch NMT1
DgiDB (Drug Gene Interaction Database)NMT1
DoCM (Curated mutations)NMT1 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)NMT1 (select a term)
NCG5 (London)NMT1
Cancer3DNMT1(select the gene name)
Impact of mutations[PolyPhen2] [Provean] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Genetic Testing Registry NMT1
NextProtP30419 [Medical]
Target ValidationNMT1
Huge Navigator NMT1 [HugePedia]
snp3D : Map Gene to Disease4836
BioCentury BCIQNMT1
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD4836
Chemical/Pharm GKB GenePA31661
Clinical trialNMT1
canSAR (ICR)NMT1 (select the gene name)
DataMed IndexNMT1
PubMed98 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Wed Nov 13 21:43:36 CET 2019

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us